Kyung Hee University

Four Startups, Student Supporters, and Research Programs from Kyung Hee to Highlight Innovative Startup Achievements and Facilitate Global Market Expansion SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Kyung Hee University (President Jinsang Kim) is preparing to leave its mark on CES® 2025, the world's premier electronics and IT exhibition. Supported by the LINC 3.0 initiative and the University-Industrial Cooperation, this year's delegation includes innovative startups founded by Kyung Hee professors and students. The university will also send its "Kyung Hee Global AFRO!" student supporters team to assist on-site and lead its "Kyung Hee Passion-Based Leading (K-PBL)—CES 2025" program, ensuring dynamic engagement at the event. Continue Reading From Campus to CES®: KHU Startups and Students on a Global Mission Four groundbreaking startups have been selected to represent Kyung Hee at CES® 2025. These include: K BioHealthcare (KBioHC): Founded by Professor Sang-Ho Lee, College of Medicine. READYCURE Inc.: Founded by Professor Weon Kuu Chung, College of Medicine. Itphy Inc.: Founded by Professor Sung Min Rhee, College of Medicine. CaiqueTech: Founded by Taewook Lee, a student in the College of Life Sciences. These ventures exemplify Kyung Hee's commitment to transforming innovative ideas from research and education into real-world solutions. The 8th cohort of "Kyung Hee Global AFRO!" student supporters will assist startups in navigating international markets. By providing interpretation services, facilitating buyer meetings, and supporting international marketing efforts, students gain valuable global business experience, while startups benefit from enhanced opportunities for overseas expansion. This initiative is part of a broader public-private-academic partnership, aligned with government-led programs to support international market development. The "Kyung Hee Passion-Based Leading (K-PBL)—CES 2025" program, organized by the Office of Educational Innovation & Planning, centers on the theme "Discovering Global Values and Directions Unique to Kyung Hee for Saving the World." Students engage in problem-based learning to explore Kyung Hee's top research achievements, analyzing how these innovations can connect with CES's cutting-edge platform. Kyung Hee's participation in CES® 2025 reflects its dedication to fostering a unique entrepreneurial ecosystem and providing students with transformative global opportunities. "We look forward to showcasing Kyung Hee's innovative ecosystem and the global competence of our students to an international audience," said Provost for Academic Affairs (Global Campus) and LINC 3.0 Project Director, Choong Seon Hong. SOURCE Kyung Hee University WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

TUESDAY, Sept. 17, 2024 -- A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with chronic hepatitis B (CHB), according to a study published online Sept. 17 in the Annals of Internal Medicine . Gi-Ae Kim, M.D., Ph.D., from Kyung Hee University Hospital in Seoul, South Korea, and colleagues developed and externally validated a prognostic model for HCC risk in noncirrhotic adult patients with CHB, without notable alanine aminotransferase (ALT) elevation. The model was developed in 6,949 patients with CHB from a Korean hospital-based cohort, and was validated externally among 7,429 patients with CHB combined from the Taiwanese cohort and seven cohorts from Korea and Hong Kong. The researchers found that the derivation and validation cohorts identified 435 and 467 incident HCC cases over 10 and 12 years, respectively. One of the strongest predictors of HCC development was baseline hepatitis B virus DNA level, which demonstrated a nonlinear parabolic association in both cohorts, with the highest risk seen for moderate viral loads. Age, sex, platelet count, ALT levels, and positive hepatitis B e antigen result were additional predictors included in the new model. Satisfactory discrimination and calibration were exhibited by the model, with c-statistics of 0.844 and 0.813 in the derivation and validation cohorts, respectively, with multiple imputation. Greater positive net benefit was yielded in the model compared with other strategies in the 0 to 18 percent threshold. "This model has the potential to inform optimal medical management strategies for patients with CHB who do not meet the current criteria for antiviral treatment," the authors write.

WEDNESDAY, Sept. 4, 2024 -- First-generation antihistamines are associated with a higher seizure risk in young children, according to a study published online Aug. 28 in JAMA Network Open . Ju Hee Kim, M.D., from the Kyung Hee University Medical Center in Seoul, South Korea, and colleagues evaluated associations between prescriptions of first-generation antihistamines and seizures in children. The analysis included data from the National Health Insurance Service database in Korea for children born in 2002 through 2005, who visited the emergency department for seizure events through 2019. The researchers identified 11,729 children who had a seizure event and were prescribed antihistamines during the hazard period (one to 15 days before seizure; 1,476 children) or the control period (31 to 45 days before seizure [1,239 children] or 61 to 75 days before seizure [1,278 children]), but not both. Most seizure events occurred in children aged 6 to 24 months (31.0 percent) and 25 months to 6 years (45.5 percent). First-generation antihistamine prescription was associated with an increased seizure event risk during the hazard period (adjusted odds ratio [aOR], 1.22). This risk was even higher in children aged 6 to 24 months who were prescribed first-generation antihistamines (aOR, 1.49) versus children aged 25 months to 6 years (aOR, 1.11). "These findings emphasize the need for careful and judicious prescription of first-generation antihistamines in young children and underline the need for further research to elucidate associations between antihistamine prescriptions and seizure risk," the authors write. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.